The US Lactase Market was valued at USD 532 million in 2025 and is projected to reach USD 1,274 million by 2035, growing at a CAGR of 8.2% from 2024 to 2035. Rising prevalence of lactose intolerance and increased demand for lactose-free dairy products are key drivers of market growth. Major players such as DuPont (IFF) and DSM are focusing on innovations to expand their product portfolios and market reach.
The economic impact of tariffs on "US Lactase Market".
US Lactase Market Growth Drivers
Rising Prevalence of Lactose Intolerance: According to the National Institutes of Health, approximately 36% of Americans suffer from some degree of lactose intolerance, leading to a significant rise in demand for lactase enzymes to produce digestible dairy products. Companies such as DuPont (now part of IFF) are investing in advanced lactase enzymes that enhance product efficacy and address broader consumer needs.
Expansion of Lactose-Free Product Portfolio: Leading dairy processors, like Danone North America, are increasingly expanding their lactose-free product offerings, including milk, yogurt, and cheese, to capture a wide consumer base. This expansion, supported by partnerships with enzyme innovators like DSM, is accelerating adoption of lactase enzymes in the U.S. food industry.
US Lactase Market Trends
Clean-Label and Non-GMO Lactase Enzymes: There is heightened demand for clean-label and non-GMO lactase solutions, leading enzyme manufacturers such as Novozymes to launch natural and non-GMO verified enzyme products. This trend aligns with consumer preferences for transparency and safer ingredient sourcing in lactose-free dairy.
Expansion Into Plant-Based and Nutraceutical Applications: Companies like Kerry Group are innovating with lactase enzymes tailored for plant-based and nutraceutical products. As consumers search for digestibility solutions in non-dairy and plant-forward categories, formulation of versatile lactase enzymes is becoming an important market trend.
US Lactase Market Opportunities
Growing E-commerce and Direct-to-Consumer Channels: With the rise in online grocery sales, companies such as Amazon Fresh and Instacart are boosting the availability and visibility of lactose-free dairy products, creating new opportunities for lactase enzyme manufacturers.
Private Label Brand Expansion: Retailers like Kroger are increasing their private label lactose-free product range, opening avenues for lactase enzyme suppliers to collaborate with in-house manufacturing teams for customized solutions.
US Lactase Market Revenue (USD Million), 2020-2035
The revenue trajectory of the US Lactase Market showed steady growth from 2020 (USD 312 million) to 2025 (USD 532 million), with a sharp upward trend projected through 2035, reaching USD 1,274 million. Key drivers include increased awareness of lactose intolerance, evolving clean-label trends, and strategic expansion by industry giants. Accelerated adoption in alternative dairy segments such as plant-based drinks and functional foods has further catalyzed the market. The period between 2025 and 2030 is anticipated to witness rapid growth, owing to new product launches and wider consumer penetration. From 2030 to 2035, continued innovation and greater consumer outreach are expected to maintain robust market momentum.
US Lactase Market by Region Share (%), 2025
The 2025 US Lactase Market regional share is dominated by the West (32%) and the South (27%), reflecting high concentration of lactose-intolerant populations and dairy innovation hubs in states like California and Texas. The Midwest (20%) leverages its strong dairy processing infrastructure, while the Northeast (17%) capitalizes on growing consumer awareness and health trends. Other regions collectively contribute about 4%, indicating smaller but emerging markets. This distribution denotes regional disparities in health trends, dairy preferences, and market penetration strategies of leading suppliers.
US Lactase Market Recent Developments
In April 2024, DSM-Firmenich announced the launch of a new advanced lactase enzyme under its Maxilact® brand, designed to ensure superior performance in lactose-free dairy processing while meeting stringent clean-label standards. The new product is anticipated to enhance efficiency for dairy manufacturers and support greater expansion in the lactose-free market segment.
In January 2024, IFF unveiled a collaboration with a major US dairy cooperative to co-develop lactase-enhanced dairy beverages, focusing on improved taste, reduced sugar, and extended shelf life. This initiative leverages IFF's leading enzyme expertise and aligns with the cooperative’s commitment to innovation in dairy alternatives.
In March 2024, Novozymes received Non-GMO Project Verification for its flagship lactase enzyme, expanding its appeal among health-conscious producers and consumers. The certification underlines the company’s dedication to clean-label solutions and is anticipated to drive further adoption of its lactase products across the US dairy sector.
Press Releases